Introduction The favorable results that have been attributed to ataractic drugs in the treatment of chronic schizophrenic patients have led to numerous investigations to determine the psychological action of these agents. "Objective" studies designed to assess psychological effects occurring with such drug therapy have demonstrated few significant changes. "Subjective" clinical methods commonly employed are vulnerable to bias, as shown by Feldman.3Some reported results are open to question because of faulty experimental design. As an applicable research design, the "double-blind" approach has important shortcomings, most noteworthy of which is that the investigator is seldom unaware of the drug group. Hall and Dunlap,5using a double-blind approach, administered chlorpromazine in individually determined doses, up to 600 mg. daily, to a large number of semidisturbed schizophrenic patients and found significant improvement at the 5% level on subjective ratings by psychiatrists and a psychologist. However, agreement between raters was attained only